A high content screening assay for identifying lysosomotropic compounds

Toxicology in Vitro

Volumn 25, Issue 3, 2011, Pages 715-723

  Nadanaciva, Sashi ^a   Lu, Shuyan ^a   Gebhard, David F ^a   Jessen, Bart A ^a   Pennie, William D ^a   Will, Yvonne ^a  

^a PFIZER INC   (United States)

Author keywords

High content screening; Lysosome; Lysosomotropism

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTIDEPRESSANT AGENT; ANTINEOPLASTIC AGENT; DASATINIB; GEFITINIB; LAPATINIB; NEUROLEPTIC AGENT;

ANIMAL CELL; ARTICLE; CELL ASSAY; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACCUMULATION; DRUG IDENTIFICATION; HIGH THROUGHPUT SCREENING; IMAGE ANALYSIS; LYSOSOME; NONHUMAN; PHYSICAL CHEMISTRY; PKA; PROCESS DEVELOPMENT; QUANTITATIVE ANALYSIS; RAT;

ANIMALS; CELL LINE; HIGH-THROUGHPUT SCREENING ASSAYS; LYSOSOMES; RATS; TOXICITY TESTS; XENOBIOTICS;

EID: 79952037605     PISSN: 08872333     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tiv.2010.12.010     Document Type: Article

References (36)

1. Chapuy B., Panse M., Radunski U., Koch R., Wenzel D., Inagaki N., et al. ABC transporter A3 facilitates lysosomal sequestration of imatinib and modulates susceptibility of chronic myeloid leukemia cell lines to this drug. Haematological 2009, 94:1528-1536.
2. Daniel W.A. Mechanisms of cellular distribution of psychotropic drugs, significance for drug action and interactions. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2003, 27:65-73.
3. Daniel W.A., Bickel M.H., Honegger U.E. The contribution of lysosomal trapping in the uptake of desipramine and chloroquine by different tissues. Pharmacology and Toxicology 1995, 77:402-406.
4. Daniel W.A., Wojcikowski J. Contribution of lysosomal trapping to the total tissue uptake of psychotropic drugs. Pharmacology and Toxicology 1997, 80:62-68.
5. Daniel W.A., Wojcikowski J. The role of lysosomes in the cellular distribution of thioridazine and potential drug interactions. Toxicology and Applied Pharmacology 1999, 158:115-124.
6. de Duve C. Lysosomes revisited. European Journal of Biochemistry 1983, 137:391-397.
7. de Duve C., de Barsy T., Poole B., Trouet A., Tulkens P., Van Hoof F. Commentary. Lysosomotropic agents. Biochemical Pharmacology 1974, 23:2495-2531.
8. De Meyer G.R., De Keulenaer G.W., Martinet W. Role of autophagy in heart failure associated with aging. Heart Failure Reviews 2010, 15:423-430.
9. Duvvuri M., Konkar S., Funk R.S., Krise J.M., Krise J.P. A chemical strategy to manipulate the intracellular localization of drugs in resistant cancer cells. Biochemistry 2005, 44:15743-15749.
10. Duvvuri M., Krise J.P. A novel assay reveals that weakly basic model compounds concentrate in lysosomes to an extent greater than pH-partitioning theory would predict. Molecular Pharmaceutics 2005, 2:440-448.
11. Erdal H., Berndtsson M., Castro J., Brunk U., Shoshan M.C., Linder S. Induction of lysosomal membrane permeabilization by compounds that activate p53-independent apoptosis. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:192-197.
12. Groth-Pedersen L., Jaattela M. Combating apoptosis and multidrug resistant cancers by targeting lysosomes. Cancer Letters 2010, [Epub ahead of print].
13. Ishizaki J., Yokogawa K., Hirano M., Nakashima E., Sai Y., Ohkuma S., et al. Contribution of lysosomes to the subcellular distribution of basic drugs in the rat liver. Pharmaceutical Research 1996, 13:902-906.
14. Ishizaki J., Yokogawa K., Ichimura F., Ohkuma S. Uptake of imipramine in rat liver lysosomes in vitro and its inhibition by basic drugs. Journal of Pharmacology and Experimental Therapeutics 2000, 294:1088-1098.
15. Kaufmann A.M., Krise J.P. Lysosomal sequestration of amine-containing drugs: analysis and therapeutic implications. Journal of Pharmaceutical Sciences 2007, 96:729-746.
16. Kirkegaard T., Jaattela M. Lysosomal involvement in cell death and cancer. Biochimica et Biophysica Acta 2009, 1793:746-754.
17. Kodavanti U.P., Mehendale H.M. Cationic amphiphilic drugs and phospholipid storage disorder. Pharmacological Reviews 1990, 42:327-354.
18. Kornhuber J., Tripal P., Reichel M., Terfloth L., Bleich S., Wiltfang J., et al. Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model. Journal of Medicinal Chemistry 2008, 51:219-237.
19. Kroemer G., Jaattela M. Lysosomes and autophagy in cell death control. Nature Reviews Cancer 2005, 5:886-897.
20. Lemieux B., Percival M.D., Falgueyret J.P. Quantitation of the lysosomotropic character of cationic amphiphilic drugs using the fluorescent basic amine Red DND-99. Analytical Biochemistry 2004, 327:247-251.
21. Luzio J.P., Pryor P.R., Bright N.A. Lysosomes: fusion and function. Nature Reviews Molecular Cell Biology 2007, 8:622-632.
22. Moriyama Y., Takano T., Ohkuma S. Acridine orange as a fluorescent probe for lysosomal proton pump. Journal of Biochemistry 1982, 92:1333-1336.
23. Ouedraogo G., Morliere P., Bazin M., Santus R., Kratzer B., Miranda M.A., et al. Lysosomes are sites of fluoroquinolone photosensitization in human skin fibroblasts: a microspectrofluorometric approach. Photochemistry and Photobiology 1999, 70:123-129.
24. Puissant A., Colosetti P., Robert G., Cassuto J.P., Raynaud S., Auberger P. Cathepsin B release after imatinib-mediated lysosomal membrane permeabilization triggers BCR-ABL cleavage and elimination of chronic myelogenous leukemia cells. Leukemia 2010, 24:115-124.
25. Puissant A., Dufies M., Raynaud S., Cassuto J.P., Auberger P. Targeting lysosomes to eradicate imatinib-resistant chronic myelogenous leukemia cells. Leukemia 2010, 24:1099-1101.
26. Reasor M.J., Hastings K.L., Ulrich R.G. Drug-induced phospholipidosis: issues and future directions. Expert Opinion on Drug Safety 2006, 5:567-583.
27. Rubinsztein D.C., Gestwicki J.E., Murphy L.O., Klionsky D.J. Potential therapeutic applications of autophagy. Nature Reviews Drug Discovery 2007, 6:304-312.
28. Turk B., Turk V. Lysosomes as " suicide bags" in cell death: myth or reality?. Journal of Biological Chemistry 2009, 284:21783-21787.
29. Wager T.T., Chandrasekaran R.Y., Hou X., Troutman M.D., Verhoest P.R., Villalobos A., et al. Defining desirable central nervous system drug space through the alignment of molecular properties, in vitro ADME, and safety attributes. ACS Chemical Neuroscience 2010, 1:420-433.
30. Walkley S.U. Pathogenic cascades in lysosomal disease - Why so complex?. Journal of Inherited Metabolic Disease 2009, 32:181-189.
31. Walls K.C., Ghosh A.P., Franklin A.V., Klocke B.J., Ballestas M., Shacka J.J., et al. Lysosome dysfunction triggers Atg7-dependent neural apoptosis. Journal of Biological Chemistry 2010, 285:10497-10507.
32. Wojcikowski J., Daniel W.A. Thioridazine-fluoxetine interaction at the level of the distribution process in vivo. Polish Journal of Pharmacology 2002, 54:647-654.
33. Yoshimori T., Yamamoto A., Moriyama Y., Futai M., Tashiro Y. Bafilomycin A1, a specific inhibitor of vacuolar-type H(+)-ATPase, inhibits acidification and protein degradation in lysosomes of cultured cells. Journal of Biological Chemistry 1991, 266:17707-17712.
34. Zhang J.H., Chung T.D., Oldenburg K.R. A Simple statistical parameter for use in evaluation and validation of high throughput screening assays. Journal of Biomolecular Screening 1999, 4:67-73.
35. Zhao B., Chignell C.F., Rammal M., Smith F., Hamilton M.G., Andley U.P., et al. Detection and prevention of ocular phototoxicity of ciprofloxacin and other fluoroquinolone antibiotics. Photochemistry and Photobiology 2010, 86:798-805.
36. Zhao Y., Xue T., Yang X., Zhu H., Ding X., Lou L., et al. Autophagy plays an important role in Sunitinib-mediated cell death in H9c2 cardiac muscle cells. Toxicology and Applied Pharmacology 2010, 248:20-27.